Herceptin [trastuzumab] (NSC 688097) and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/NEU
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Gemcitabine (Primary) ; Trastuzumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Dec 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified Dec 2002).
- 09 Sep 2005 New trial record.